<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535908</url>
  </required_header>
  <id_info>
    <org_study_id>1091/2020</org_study_id>
    <nct_id>NCT04535908</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.</brief_title>
  <official_title>Clinical Study to Evaluate Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of all new prostate cancer cases are diagnosed in men aged &gt; 70 years, with the&#xD;
      highest incidence in men aged &gt; 90 years. Management options for localized prostate cancer&#xD;
      include active surveillance in patients with low-risk disease, radical prostatectomy or&#xD;
      external beam radiation therapy.&#xD;
&#xD;
      In previous studies, hypofractionated prostate cancer irradiation regimens have been shown to&#xD;
      represent a highly effective treatment option for prostate cancer. However, patients aged 75&#xD;
      years or older were underrepresented in most trials resulting in the lack of a robust&#xD;
      evidence base.&#xD;
&#xD;
      The proposed study will evaluate radiation-induced toxicity as well as outcome after&#xD;
      hypofractionated external beam radiotherapy in prostate cancer patients aged 75 years or&#xD;
      older.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute radiation - induced toxicity</measure>
    <time_frame>Measurement at the last 1 day of radiotherapy</time_frame>
    <description>Toxicity score using Common Terminology for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute radiation - induced toxicity</measure>
    <time_frame>Measurement 3 months after completion of radiotherapy</time_frame>
    <description>Toxicity score using Common Terminology for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 1, 2, 3 , 4, 5 years after completion of radiotherapy</time_frame>
    <description>Analysis of survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence (biochemical)</measure>
    <time_frame>At 1, 2, 3 , 4, 5 years after completion of radiotherapy</time_frame>
    <description>Assessed by measurement of prostate specific antigen (PSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence (local)</measure>
    <time_frame>At 1, 2, 3 , 4, 5 years after completion of radiotherapy</time_frame>
    <description>Assessed by magnetic resonance imaging (MRI), positron emission tomography (optional)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Radiotherapy Side Effect</condition>
  <arm_group>
    <arm_group_label>Hypofractionated radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiotherapy</intervention_name>
    <description>Hypofractionated radiotherapy in prostate cancer patients</description>
    <arm_group_label>Hypofractionated radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed prostate cancer adenocarcinoma&#xD;
&#xD;
          -  definitive radiotherapy for curative intent&#xD;
&#xD;
          -  low or intermediate risk prostate cancer&#xD;
&#xD;
          -  patient age â‰¥ 75 years&#xD;
&#xD;
          -  given informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic inflammatory bowel disease&#xD;
&#xD;
          -  high risk prostate cancer&#xD;
&#xD;
          -  lymph node or distant metastases&#xD;
&#xD;
          -  unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja Langsenlehner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Dept. of Therapeutic Radiology and Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanja Langsenlehner, MD</last_name>
    <phone>0043 316 385 87869</phone>
    <email>tanja.langsenlehner@medunigraz.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Langsenlehner, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20. Erratum in: Lancet Oncol. 2016 Aug;17 (8):e321.</citation>
    <PMID>27339115</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypofractionated radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

